UK markets closed

KALA BIO, Inc. (0JQ2.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
7.58-0.02 (-0.26%)
At close: 06:27PM BST
Full screen
Previous close7.60
Open7.79
BidN/A x N/A
AskN/A x N/A
Day's range7.58 - 7.79
52-week range5.27 - 19.48
Volume752
Avg. volume320
Market capN/A
Beta (5Y monthly)-2.04
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    KALA BIO Announces $12,500,000 Private Placement

    ARLINGTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for the sale, in a private placement, of shares of its common stock and shares of its Series H Convertible Non-Redeema

  • GlobeNewswire

    KALA BIO to Present at Jefferies Global Healthcare Conference

    ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be av

  • GlobeNewswire

    KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

    -- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD and to explore KPI-014 in rare inherited retinal diseases -- -- Cash resources of $48.5 million as of March 31, 2024 together with anticipated funding remaining from CIRM award expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- KALA BIO